Tim Forshew

Tim Forshew

Auto-generated profile, based on publicly available information

Tim Forshew

Research and Development, Inivata Ltd, Granta Park, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SDSarah-Jane Dawson
Sarah-Jane Dawson
DTDana W.Y. Tsui
Dana W.Y. Tsui
MMMuhammed Murtaza
Muhammed Murtaza
HBHeather Biggs
Heather Biggs
OROscar M. Rueda
Oscar M. Rueda
NRNitzan Rosenfeld
Nitzan Rosenfeld
The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied. However, circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer. We compared the radiographic imaging of tumors with the assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic breast cancer who were receiving systemic therapy. We used targeted or whole-genome sequencing to identify somatic genomic alterations and designed personalized assays to quantify circulating tumor DNA in serially collected plasma specimens. CA 15-3 levels and numbers of circulating tumor cells were measured at identical time points. Circulating tumor DNA was successfully detected in 29 of the 30 women (97%) in whom somatic genomic alterations were identified; CA 15-3 and circulating tumor cells were detected in 21 of 27 women (78%) and 26 of 30 women (87%), respectively. Circulating tumor DNA levels showed a greater dynamic range, and greater correlation with changes in tumor burden, than did CA 15-3 or circulating tumor cells. Among the measures tested, circulating tumor DNA provided the earliest measure of treatment response in 10 of 19 women (53%). This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer. (Funded by Cancer Research UK and others.)

7 April 2013 in Nature
Verified
Journal Article
Closed access
MMMuhammed Murtaza
Muhammed Murtaza
SDSarah-Jane Dawson
Sarah-Jane Dawson
DTDana W. Y. Tsui
Dana W. Y. Tsui
DGDavina Gale
Davina Gale
TFTim Forshew
Tim Forshew
NRNitzan Rosenfeld
Nitzan Rosenfeld

30 May 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
TFTim Forshew
Tim Forshew
MMMuhammed Murtaza
Muhammed Murtaza
CPChristine Parkinson
Christine Parkinson
DGDavina Gale
Davina Gale
DTDana W. Y. Tsui
Dana W. Y. Tsui
NRNitzan Rosenfeld
Nitzan Rosenfeld
Plasma of cancer patients contains cell-free tumor DNA that carries information on tumor mutations and tumor burden. Individual mutations have been probed using allele-specific assays, but sequencing of entire genes to detect cancer mutations in circulating DNA has not been demonstrated. We developed a method for tagged-amplicon deep sequencing (TAm-Seq) and screened 5995 genomic bases for low-frequency mutations. Using this method, we identified cancer mutations present in circulating DNA at allele frequencies as low as 2%, with sensitivity and specificity of >97%. We identified mutations throughout the tumor suppressor gene TP53 in circulating DNA from 46 plasma samples of advanced ovarian cancer patients. We demonstrated use of TAm-Seq to noninvasively identify the origin of metastatic relapse in a patient with multiple primary tumors. In another case, we identified in plasma an EGFR mutation not found in an initial ovarian biopsy. We further used TAm-Seq to monitor tumor dynamics, and tracked 10 concomitant mutations in plasma of a metastatic breast cancer patient over 16 months. This low-cost, high-throughput method could facilitate analysis of circulating DNA as a noninvasive “liquid biopsy” for personalized cancer genomics.

1 May 2013 in Cancer Cell
Verified
Journal Article
Closed access
TCTomer Cooks
Tomer Cooks
IPIoannis S. Pateras
Ioannis S. Pateras
OTOhad Tarcic
Ohad Tarcic
HSHilla Solomon
Hilla Solomon
ASAaron J. Schetter
Aaron J. Schetter
MOMoshe Oren
Moshe Oren

22 June 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCthe OCCAMS Consortium
the OCCAMS Consortium
JWJamie M J Weaver
Jamie M J Weaver
CRCaryn S Ross-Innes
Caryn S Ross-Innes
NSNicholas Shannon
Nicholas Shannon
ALAndy Lynch
Andy Lynch
RFRebecca C Fitzgerald
Rebecca C Fitzgerald
Rebecca Fitzgerald and colleagues used genome sequence analyses to study the progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) and found that the majority of recurrently mutated genes in EAC were also mutated in precursor lesions and that only mutations in TP53 and SMAD4 were stage specific. Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) provides an ideal model to study the ordering of somatic mutations. We identified recurrently mutated genes and assessed clonal structure using whole-genome sequencing and amplicon resequencing of 112 EACs. We next screened a cohort of 109 biopsies from 2 key transition points in the development of malignancy: benign metaplastic never-dysplastic Barrett's esophagus (NDBE; n = 66) and high-grade dysplasia (HGD; n = 43). Unexpectedly, the majority of recurrently mutated genes in EAC were also mutated in NDBE. Only TP53 and SMAD4 mutations occurred in a stage-specific manner, confined to HGD and EAC, respectively. Finally, we applied this knowledge to identify high-risk Barrett's esophagus in a new non-endoscopic test. In conclusion, mutations in EAC driver genes generally occur exceptionally early in disease development with profound implications for diagnostic and therapeutic strategies.

28 March 2004 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
Paul GissenPaul Gissen
Paul Gissen
CJColin A Johnson
Colin A Johnson
NMNeil Morgan
Neil Morgan
JSJanneke M Stapelbroek
Janneke M Stapelbroek
TFTim Forshew
Tim Forshew
EMEamonn Richard Maher
Eamonn Richard Maher